We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Use of pretreatment serum uric acid level to predict metastasis in locally advanced nasopharyngeal carcinoma.
- Authors
Du, Xiao ‐ Jing; Chen, Lei; Li, Wen ‐ Fei; Tang, Ling ‐ Long; Mao, Yan ‐ Ping; Guo, Rui; Sun, Ying; Lin, Ai ‐ Hua; Ma, Jun
- Abstract
Background The purpose of this study was to determine the predictive value of pretreatment serum uric acid (SUA) for metastasis in locally advanced nasopharyngeal carcinoma (NPC) treated with intensity-modulated radiotherapy. Methods This retrospective study examined 1063 patients with locally advanced NPC. Multivariate survival analysis was used. Results High pretreatment SUA level (>353.4 μmol/L) independently predicted distant metastasis-free survival ( p = .013) and was associated with high white blood cell ( p = .005), lymphocyte counts ( p < .001), and male sex ( p < 0.001). In addition, SUA levels were significantly elevated in patients with T1 to T3 classification ( p = .042). For patients with subsequent lung metastases after treatment, markedly higher pretreatment SUA levels were detected compared with patients who had other distant metastases ( p =.012) and patients without distant metastasis ( p = .024). Conclusion Pretreatment SUA may be a useful biomarker for evaluating treatment options for patients with locally advanced NPC. © 2016 Wiley Periodicals, Inc. Head Neck 39: 492-497, 2017
- Subjects
URIC acid; METASTASIS; INTENSITY modulated radiotherapy; RETROSPECTIVE studies; LEUKOCYTE count; DIAGNOSIS
- Publication
Head & Neck, 2017, Vol 39, Issue 3, p492
- ISSN
1043-3074
- Publication type
Article
- DOI
10.1002/hed.24631